Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most factual statements (active ingredient, atypical antipsychotic, MDD adjunctive indication, schizophrenia indication) align with the provided label excerpts. However, the dementia-related boxed warning and mechanism wording are not fully or clearly supported by the provided label text, and the generic-availability and manufacturer claims are not supported by the supplied label content.
Category Scores
Accurate Statements
Rexulti is indicated as an adjunctive treatment for major depressive disorder (MDD) in adults.
Label section 1 INDICATIONS AND USAGE: “Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults.”
Rexulti is indicated for the treatment of schizophrenia in adults.
Label section 1 INDICATIONS AND USAGE: “Treatment of schizophrenia in adults and pediatric patients ages 13 years and older.”
The active ingredient in Rexulti is brexpiprazole.
Label section 11 DESCRIPTION: “Brexpiprazole, an atypical antipsychotic, is available as REXULTI® (brexpiprazole) tablets.”
Rexulti is classified as an atypical antipsychotic.
Label section 11 DESCRIPTION: “Brexpiprazole, an atypical antipsychotic, is available as REXULTI® (brexpiprazole) tablets.”
Rexulti has a boxed warning highlighting an increased risk of death in elderly patients with dementia-related psychosis.
Label WARNING heading: “INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS …”
Unsupported Statements
Rexulti (brexpiprazole) is not yet available in generic form.
No information about generic availability is provided in the supplied label excerpts.
Rexulti is manufactured by Otsuka Pharmaceutical Co., Ltd.
No manufacturer information is provided in the supplied label excerpts.
Contradictions
Low
AI Statement
The mechanism of Rexulti is thought to work by affecting the activity of dopamine and serotonin neurotransmitters in the brain.
Label Reference
Label section 12.1 Mechanism of Action states: “efficacy … may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors,” and also notes the mechanism of action is unknown.
Important Omissions
For the boxed warning claim, the AI did not mention the “suicidal thoughts and behaviors” component included in the provided WARNING heading.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The boxed warning statement is partially supported, but the response does not include the full warning heading content provided (“suicidal thoughts and behaviors”). Several other statements are unsupported by the provided label excerpts (generic availability, manufacturer), which could mislead without changing direct medication safety content. The mechanism statement does not fully reflect the label’s receptor-specific, “unknown mechanism” framing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Mechanism-of-action phrasing and completeness of the boxed warning are not fully aligned with the supplied label text, and generic-manufacturer claims are unsupported by the provided excerpts.
Suggested Improvement
Use the label’s exact framing for mechanism (“mechanism … is unknown” and receptor-specific partial agonist/antagonist activities). For the boxed warning, include both “INCREASED MORTALITY … dementia-related psychosis” and “SUICIDAL THOUGHTS AND BEHAVIORS” as shown in the provided WARNING heading. Remove or qualify statements about generic availability and manufacturer unless supported by the label text.